M Imad Damaj Selected Research

Nicotine

1/2021	Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms.
10/2020	Inhibition of monoacylglycerol lipase reduces nicotine reward in the conditioned place preference test in male mice.
1/2020	A silent agonist of α7 nicotinic acetylcholine receptors modulates inflammation ex vivo and attenuates EAE.
1/2020	Impact of Menthol on Oral Nicotine Consumption in Female and Male Sprague Dawley Rats.
12/2019	Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.
10/2019	Assessing nicotine dependence using an oral nicotine free-choice paradigm in mice.
10/2019	The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal.
9/2019	C57BL/6 Substrain Differences in Pharmacological Effects after Acute and Repeated Nicotine Administration.
1/2019	The β3 subunit of the nicotinic acetylcholine receptor is required for nicotine withdrawal-induced affective but not physical signs or nicotine reward in mice.
10/2018	Early adolescent nicotine exposure affects later-life hippocampal mu-opioid receptors activity and morphine reward but not physical dependence in male mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Imad Damaj Research Topics

Disease

25	Pain (Aches) 06/2022 - 09/2003
23	Tobacco Use Disorder (Nicotine Dependence) 01/2022 - 03/2005
19	Hyperalgesia 06/2022 - 03/2005
13	Peripheral Nervous System Diseases (PNS Diseases) 06/2022 - 10/2015
12	Neuralgia (Stump Neuralgia) 01/2021 - 08/2006
10	Neoplasms (Cancer) 06/2022 - 11/2016
10	Inflammation (Inflammations) 06/2022 - 08/2006
9	Hypersensitivity (Allergy) 06/2022 - 01/2019
9	Hypothermia 09/2019 - 09/2003
8	Chronic Pain 01/2020 - 08/2006
4	Edema (Dropsy) 01/2021 - 10/2015
4	Alcoholism (Alcohol Abuse) 09/2019 - 03/2013
4	Acquired Immunodeficiency Syndrome (AIDS) 01/2019 - 06/2010
3	Neuroinflammatory Diseases 06/2022 - 12/2020
3	Cold Hypersensitivity 06/2022 - 12/2020
3	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2022 - 10/2018
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2019 - 01/2018
3	Substance-Related Disorders (Drug Abuse) 10/2018 - 10/2011
3	Colitis 04/2017 - 09/2010
2	Opioid-Related Disorders (Opiate Addiction) 01/2022 - 07/2021
2	Dyslipidemias (Dyslipidemia) 01/2021 - 12/2020
2	Schizophrenia (Dementia Praecox) 01/2020 - 06/2007
2	Binge Drinking 10/2019 - 01/2019
2	Anhedonia 01/2019 - 01/2017
2	Ovarian Neoplasms (Ovarian Cancer) 01/2018 - 01/2017
2	Mood Disorders (Mood Disorder) 01/2017 - 10/2015
2	Cocaine-Related Disorders (Cocaine Addiction) 01/2014 - 12/2010
2	Ulcerative Colitis 01/2013 - 09/2010
2	Acute Pain 09/2012 - 10/2004
2	Seizures (Absence Seizure) 09/2003 - 04/2003
1	Diarrhea 01/2022
1	Weight Loss (Weight Reduction) 01/2022
1	Breast Neoplasms (Breast Cancer) 12/2020
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2020
1	Body Weight Changes 01/2020
1	Autistic Disorder (Autism) 01/2020

Drug/Important Bio-Agent (IBA)

40	Nicotine FDA Link 01/2021 - 04/2003
25	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 06/2022 - 04/2003
12	Paclitaxel (Taxol)FDA LinkGeneric 06/2022 - 11/2016
10	Pharmaceutical PreparationsIBA 01/2021 - 06/2007
8	Formaldehyde (Formol)FDA Link 01/2020 - 09/2012
6	Varenicline (Chantix)FDA Link 01/2018 - 12/2010
5	Analgesics (Analgesic Drugs)IBA 01/2021 - 09/2012
5	Freund's AdjuvantIBA 01/2020 - 10/2015
5	Cocaine (Cocaine HCl)IBA 01/2020 - 09/2003
5	Ethanol (Ethyl Alcohol)IBA 12/2019 - 03/2013
5	Bupropion (Wellbutrin)FDA LinkGeneric 01/2014 - 06/2010
4	Sucrose (Saccharose)IBA 01/2021 - 01/2017
4	LigandsIBA 01/2020 - 12/2010
4	Morphine (MS Contin)FDA LinkGeneric 01/2020 - 01/2016
4	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 12/2019 - 03/2011
3	Menthol FDA Link 01/2022 - 01/2015
3	Opioid Analgesics (Opioids)IBA 01/2022 - 01/2016
3	Fenofibrate (CiL)FDA LinkGeneric 01/2021 - 01/2017
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2021 - 01/2017
3	Choline (Choline Chloride)IBA 01/2021 - 01/2013
3	Acetic Acid (Vinegar)FDA LinkGeneric 01/2019 - 04/2015
3	MecamylamineIBA 01/2018 - 03/2005
3	1- (5- chloro- 2,4- dimethoxyphenyl)- 3- (5- methylisoxazol- 3- yl)ureaIBA 01/2018 - 01/2013
3	sodium sulfate (sodium bisulfate)FDA LinkGeneric 04/2017 - 09/2010
3	Dextrans (Dextran)FDA Link 04/2017 - 09/2010
3	CarrageenanIBA 11/2015 - 08/2006
3	cocaine- and amphetamine-regulated transcript protein (55-102)IBA 08/2006 - 09/2003
2	CurcuminIBA 06/2022 - 10/2020
2	CannabinoidsIBA 01/2022 - 01/2018
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2022 - 01/2018
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 01/2021
2	fenofibric acid FDA Link 01/2021 - 12/2020
2	Cholinergic Agents (Cholinergics)IBA 01/2020 - 01/2013
2	SolutionsIBA 01/2020 - 04/2017
2	Antineoplastic Agents (Antineoplastics)IBA 10/2019 - 11/2016
2	1,4- diazabicyclo(3.2.2)nonan- 4- yl(5- (3- (trifluoromethyl)phenyl)furan- 2- yl)methanoneIBA 01/2018 - 04/2015
2	1- (5- chloro- 2- hydroxyphenyl)- 3- (2- chloro- 5- trifluoromethylphenyl)ureaIBA 01/2018 - 01/2013
2	4- (4- bromophenyl)- 3a,4,5,9b- tetrahydro- 3H- cyclopenta(c)quinoline- 8- sulfonamideIBA 01/2018 - 01/2016
2	CotinineIBA 06/2017 - 01/2013
2	Antidepressive Agents (Antidepressants)IBA 01/2014 - 06/2010
2	hydroxybupropionIBA 09/2010 - 06/2010
2	epibatidineIBA 03/2010 - 06/2006
2	Peptides (Polypeptides)IBA 08/2006 - 10/2004
2	Amphetamine (Amfetamine)FDA LinkGeneric 10/2004 - 09/2003
1	AntioxidantsIBA 06/2022
1	PolyphenolsIBA 06/2022
1	Neuroprotective AgentsIBA 06/2022
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2022
1	AntidiarrhealsIBA 01/2022
1	Naloxone (Narcan)FDA LinkGeneric 01/2022
1	Oxycodone (Oxycontin)FDA LinkGeneric 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	Fibric Acids (Fibrates)IBA 01/2021
1	salicylhydroxamic acid (SHAM)IBA 01/2021
1	Protein Isoforms (Isoforms)IBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 12/2020
1	CytokinesIBA 01/2020

Therapy/Procedure

12	Drug Therapy (Chemotherapy) 01/2021 - 07/2012
8	Therapeutics 01/2021 - 03/2006
3	Self Administration (Administration, Self) 01/2021 - 02/2011
3	Analgesia 12/2019 - 03/2005
2	Hypnosis (Mesmerism) 01/2018 - 03/2013
1	Injections 01/2021